Generating HIV resistant cells from conditionally transformed HSC cell lines

Information

  • Research Project
  • 7419068
  • ApplicationId
    7419068
  • Core Project Number
    R43HL091740
  • Full Project Number
    1R43HL091740-01
  • Serial Number
    91740
  • FOA Number
    PA-07-81
  • Sub Project Id
  • Project Start Date
    9/19/2008 - 16 years ago
  • Project End Date
    9/18/2010 - 14 years ago
  • Program Officer Name
    VOULGAROPOULOU, FROSSO
  • Budget Start Date
    9/19/2008 - 16 years ago
  • Budget End Date
    9/18/2010 - 14 years ago
  • Fiscal Year
    2008
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/19/2008 - 16 years ago

Generating HIV resistant cells from conditionally transformed HSC cell lines

[unreadable] DESCRIPTION (provided by applicant): Using a method of retroviral gene transduction we have been able to generate conditionally immortalized long-term hematopoietic stem cell lines from primary mouse bone marrow stem cells. Phase I of this project includes testing the same technology in human cells and the subsequent analysis of those cells in the laboratory and in mice. In addition, the project includes knockdown of HIV-1 co-receptors to generate HIV-1 resistant cells in a mouse model. The method to genetically modify the long-term hematopoietic stem cell lines includes state-of-the-art vector transduction with shRNA containing constructs. Phase II of the project will entail testing this approach in a primate model and optimizing large-scale production of genetically-modified conditionally-immortalized long-term hematopoietic stem cells for testing in clinical trials. [unreadable] [unreadable] This project seeks to refine appropriate methods to genetically manipulate conditionally immortalized hematopoietic stem cell lines to generate HIV-1 resistant cells. Once these methods have been established for the human, the long-term goal to benefit public health will be to use these cells for treating HIV-1 infected patients to re-establish a functional immune system that is protected from endogenous or exogenous sources of HIV. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    161192
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:161192\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    TAIGA BIOTECHNOLOGIES, INC.
  • Organization Department
  • Organization DUNS
    783743938
  • Organization City
    AURORA
  • Organization State
    CO
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    800457336
  • Organization District
    UNITED STATES